Tulmimetostat for Skin Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called Tulmimetostat (CPI-0209) for individuals with advanced skin conditions, specifically mycosis fungoides and Sézary syndrome. Researchers aim to determine if this medication is safe and effective for those who have not responded to other treatments. Participants will take the medication orally every day in cycles, with dosage varying based on the trial stage. This trial suits those diagnosed with mycosis fungoides or Sézary syndrome who have already undergone at least one other systemic treatment. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new medication.
Will I have to stop taking my current medications?
The trial requires a washout period (time without taking certain medications) for some treatments before starting the study drug. You may need to stop certain medications, especially if they are systemic therapies for mycosis fungoides/Sézary syndrome or strong CYP3A inducers or inhibitors. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that Tulmimetostat is likely to be safe for humans?
Research has shown that Tulmimetostat, also known as DZR123, is generally safe for use in certain cancer treatments. Previous studies found that most patients tolerated doses of 200 mg and 300 mg well, without severe side effects. Another study indicated that Tulmimetostat had a low rate of serious treatment-related side effects, making it a promising and safe option for some cancer treatments. However, this trial is in its early stages and primarily focuses on testing safety.12345
Why do researchers think this study treatment might be promising?
Unlike the standard treatments for skin cancer, which often include surgery, radiation, and chemotherapy, Tulmimetostat targets the cancer cells' genetic makeup directly. This innovative drug works by inhibiting specific enzymes that are crucial for cancer cell survival, potentially leading to fewer side effects compared to traditional therapies. Researchers are excited about Tulmimetostat because it is taken orally, making it more convenient for patients, and it has shown promise in targeting the cancer cells more precisely, which could improve treatment effectiveness and patient outcomes.
What evidence suggests that Tulmimetostat might be an effective treatment for skin cancer?
Research has shown that Tulmimetostat blocks certain proteins linked to cancer growth. In a study with patients who had various advanced cancers, Tulmimetostat shrank tumors after other treatments failed. Early results suggest it might be effective for skin cancers like mycosis fungoides (MF) and Sézary syndrome (SS) when other treatments have failed. This trial will evaluate different dosages of Tulmimetostat to determine its effectiveness and safety for advanced skin cancers. Although more research is needed, these findings suggest Tulmimetostat could be a promising option for people with advanced skin cancers.12678
Who Is on the Research Team?
Neha Mehta-shah, M.D.
Principal Investigator
Washington University School of Medicine
Are You a Good Fit for This Trial?
This trial is for adults with advanced mycosis fungoides or Sézary syndrome who have tried at least one systemic therapy. They should be relatively healthy, able to perform daily activities, and have adequate organ function and blood counts. Pregnant women can't participate, and participants must use contraception.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daily CPI-0209 by mouth for days 1-28 of each 28-day cycle. Dose will depend on dose level assignment.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Tulmimetostat
Trial Overview
The trial tests Tulmimetostat (CPI-0209) on patients with specific skin lymphomas to see if it's safe and effective after other treatments failed. It's given as a single agent, meaning no other drugs are combined in the treatment regimen.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Daily DZR123by mouth for days 1-28 of each 28-day cycle. Dose will be the maximum-tolerated dose found during the dose de-escalation cohort which was 300 mg.
Daily DZR123 by mouth for days 1-28 of each 28-day cycle. Dose will be 200 mg as the maximum tolerated dose of 300 mg found during the initial dose expansion cohort caused numerous dose reductions.
Daily DZR123 by mouth for days 1-28 of each 28-day cycle. Dose will depend on dose level assignment of 300 mg daily, 250 mg daily, or 200 mg daily.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
Swim Across America
Collaborator
The Foundation for Barnes-Jewish Hospital
Collaborator
MorphoSys AG
Industry Sponsor
Daniel E. Corbin Jr. Lymphoma Fund
Collaborator
Swim Across America
Collaborator
Novartis
Industry Sponsor
Vasant Narasimhan
Novartis
Chief Executive Officer since 2018
MD from Harvard Medical School, Bachelor's in Biological Sciences from University of Chicago, Master's in Public Policy from John F. Kennedy School of Government
Shreeram Aradhye
Novartis
Chief Medical Officer since 2022
MD from Yale University, MSc in Clinical Epidemiology from University of Pennsylvania
Citations
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients ...
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a ...
EZH2/EZH1 inhibitor tulmimetostat (CPI-0209) in patients ...
Results: As of Nov 08, 2022, 62 pts received ≥1 dose (safety evaluable); 48 had ≥1 postbaseline tumor assessment (efficacy evaluable). Pts had ...
Tulmimetostat for Skin Cancer · Recruiting Participants ...
Trial Overview The trial tests Tulmimetostat (CPI-0209) on patients with specific skin lymphomas to see if it's safe and effective after other treatments failed ...
4.
clinicaltrials.eu
clinicaltrials.eu/trial/study-of-tulmimetostat-cpi-0209-for-patients-with-advanced-solid-tumors-and-lymphomas/Study of Tulmimetostat (CPI-0209) for Patients with ...
The purpose of this study is to determine the best dose of CPI-0209 and to evaluate its effectiveness in treating these advanced cancers. The ...
FDA Grants Fast Track Status to Tulmimetostat ... - OncLive
Moreover, 77.8% of patients had TEAEs that resulted in dose modifications, 38.3% had TEAEs that required dose reductions, and 70.4% had AEs ...
Phase II dose optimization update with EZH2/EZH1 ...
Tulmimetostat showed an improved and acceptable safety profile in OCCC and EC at 200 mg and 300 mg doses (versus 350 mg) with promising antitumor activity.
Safety profile of EZH2 inhibitors for cancer - PubMed Central
EZH2 inhibitors demonstrate a manageable safety profile with a low incidence of severe TRAEs, emphasizing their potential as safe therapeutic options in cancer ...
CPI-0209 Plus Carboplatin in Patients With Platinum ...
This study aims to investigate whether CPI-0209 will enhance ovarian cancer sensitivity to platinum-based chemotherapy and prolong the disease free interval ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.